Reviva Pharmaceuticals Holdings, Inc. SEC filings RVPH
Reviva Pharmaceuticals Holdings, Inc. has 413 filings in SEC EDGAR's recent list, going back to Jun 19, 2018. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 12, 2026 (results of operations, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 25-NSE | Delisting notice | Jul 10, 2026 | — |
| 25-NSE | Delisting notice | Dec 12, 2025 | — |
| NT 10-K | Form nt 10-k | Mar 31, 2025 | Dec 31, 2024 |
| UPLOAD | Letter from the SEC | Aug 22, 2024 | — |
| CORRESP | Letter to the SEC | Aug 7, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 24, 2024 | — |
| NT 10-K | Form nt 10-k | Apr 2, 2024 | Dec 31, 2023 |
| EFFECT | Filing | Feb 13, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 9, 2024 | — |
| CORRESP | Letter to the SEC | Feb 9, 2024 | — |
| EFFECT | Filing | Apr 4, 2023 | — |
| EFFECT | Filing | Oct 17, 2022 | — |
| CORRESP | Letter to the SEC | Oct 13, 2022 | — |
| UPLOAD | Letter from the SEC | Oct 12, 2022 | — |
| D | Filing | Sep 19, 2022 | — |
| EFFECT | Filing | Mar 22, 2022 | — |
| EFFECT | Filing | Mar 22, 2022 | — |
| EFFECT | Filing | Feb 2, 2022 | — |
| CORRESP | Letter to the SEC | Jan 31, 2022 | — |
| UPLOAD | Letter from the SEC | Jan 31, 2022 | — |
| POS EX | Form pos ex | May 28, 2021 | — |
| EFFECT | Filing | May 26, 2021 | — |
| CORRESP | Letter to the SEC | May 25, 2021 | — |
| CORRESP | Letter to the SEC | May 25, 2021 | — |
| EFFECT | Filing | May 14, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 21, 2021 | — |
| EFFECT | Filing | Mar 26, 2021 | — |
| EFFECT | Filing | Jan 11, 2021 | — |
| CORRESP | Letter to the SEC | Jan 7, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 4, 2021 | — |
| 25-NSE | Delisting notice | Dec 14, 2020 | — |
| 425 | Form 8-k | Nov 19, 2020 | — |
| EFFECT | Filing | Nov 10, 2020 | — |
| CORRESP | Letter to the SEC | Nov 9, 2020 | — |
| 425 | Form 8-k | Nov 6, 2020 | — |
| UPLOAD | Letter from the SEC | Nov 5, 2020 | — |
| 425 | Form 8-k | Nov 5, 2020 | — |
| CORRESP | Letter to the SEC | Nov 2, 2020 | — |
| 425 | Form 8-k | Oct 27, 2020 | — |
| 425 | Form 8-k | Oct 22, 2020 | — |
| UPLOAD | Letter from the SEC | Oct 16, 2020 | — |
| 425 | Filing | Oct 6, 2020 | — |
| CORRESP | Letter to the SEC | Oct 5, 2020 | — |
| 425 | Form 8-k | Sep 14, 2020 | — |
| UPLOAD | Letter from the SEC | Sep 11, 2020 | — |
| 425 | Filing | Jul 29, 2020 | — |
| 425 | Form 8-k | Jul 24, 2020 | — |
| 425 | Form 8-k | Jul 21, 2020 | — |
| EFFECT | Filing | Aug 20, 2018 | — |
| CORRESP | Letter to the SEC | Aug 20, 2018 | — |
| CORRESP | Letter to the SEC | Aug 20, 2018 | — |
| CERT | Filing | Aug 20, 2018 | — |
| 8-A12B | Filing | Aug 20, 2018 | — |
| CORRESP | Letter to the SEC | Jul 20, 2018 | — |
| UPLOAD | Letter from the SEC | Jul 16, 2018 | — |
| DRS | Filing | Jun 19, 2018 | — |
Showing 56 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RVPH (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cupertino, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1742927
- Former names
- Tenzing Acquisition Corp. (until Dec 14, 2020)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.